CORRECTION article

Front. Med., 29 March 2022

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.888928

Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol

  • 1. Center for Rheumatic Diseases, Pune, India

  • 2. Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India

  • 3. Translational Health Science and Technology Institute (THSTI), Faridabad, India

  • 4. Central Council for Research in Ayurvedic Science, New Delhi, India

In the original article, there was an error in the sentence “One tablet of Ashwagandha or placebo will be administered twice daily (on empty stomach in the morning and after dinner) with water.”

The correction has been made to the Eligibility section, “Trial Intervention” sub section and the corrected sentence appears below:

“One tablet of Ashwagandha or placebo will be administered daily (on empty stomach in the morning) with water.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

COVID-19, immunogenicity, Withania somnifera, vaccine, Ayurveda, Ashwagandha, immunoadjuvant

Citation

Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao BCS, Yadav B, Srikanth N and Patwardhan B (2022) Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol. Front. Med. 9:888928. doi: 10.3389/fmed.2022.888928

Received

03 March 2022

Accepted

09 March 2022

Published

29 March 2022

Volume

9 - 2022

Edited and reviewed by

Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France

Updates

Copyright

*Correspondence: Bhushan Patwardhan

This article was submitted to Infectious Diseases Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics